ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Renoprotective effects of perampanel against cisplatin-induced acute kidney injury: managing NLRP3-pyroptosis and enhancement of antioxidant defense.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin is a highly effective chemotherapeutic agent used to treat various solid tumors; however, its clinical utility is limited by dose-dependent nephrotoxicity. Perampanel, an AMPA-receptor antagonist FDA-approved anti-seizure drug, has recently shown inhibitory effects on oxidative stress and inflammasome-mediated pyroptosis in neurological damage models. The current work examined the possible renoprotective benefits and clarified the underlying molecular signaling modified by perampanel in a cisplatin-renal injury model. Male Wistar rats were used to investigate the effect of perampanel (1 & 2 mg/kg/day, for 14 days) against renal injury induced by cisplatin (10 mg/kg, on the 9th day), followed by morphological, histopathological, immunohistochemical (IHC), and biochemical estimations. The administration of perampanel to cisplatin-injected rats maintained the kidney-to-body weight ratio and renal function in a dose-dependent manner. Besides, there was a great improvement in the histological features compared to the cisplatin group. IHC analysis revealed the efficient inhibitory impact of perampanel against cisplatin-induced upregulation of NF-κB p65, NLRP3, and caspase-1 expressions. Consequently, the activation of interleukin (IL)-18 and -1β inflammatory cytokines was interrupted, and their renal levels were not elevated. Eventually, the pyroptosis effector protein, gasdermin D (GSDMD), upregulation was impeded. Inflammasome inhibition by perampanel was accompanied by downregulation of the promoter signaling NF-κB p65/TNF-α, enhancement of sirtuin 3/FOXO3 antioxidant signaling alongside upregulated Nrf-2 mRNA expression and antioxidant proteins, as well as maintained balance of Bax/Bcl-2; pro-/anti-apoptotic; genes. Collectively, perampanel could attenuate cisplatin-induced renal injury through its inhibitory influence on NF-κB p65/TNF-α and NLRP3-mediated pyroptosis, in addition to enhancement of antioxidant defense and controlling apoptosis.
Indexed as
Identifiers
42032077What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.